CUC Inc. (TYO:9158)
Japan · Delayed Price · Currency is JPY 1,202.00
-34.00 (-2.75%)
Aug 22, 2025, 3:30 PM JST
CUC Inc. Revenue
CUC Inc. had revenue of 13.00B JPY in the quarter ending June 30, 2025, with 22.64% growth. This brings the company's revenue in the last twelve months to 49.44B, up 37.50% year-over-year. In the fiscal year ending March 31, 2025, CUC Inc. had annual revenue of 47.04B with 42.45% growth.
Revenue (ttm)
49.44B
Revenue Growth
+37.50%
P/S Ratio
0.71
Revenue / Employee
9.61M
Employees
5,145
Market Cap
35.24B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 47.04B | 14.02B | 42.45% |
| Mar 31, 2024 | 33.03B | -2.19B | -6.21% |
| Mar 31, 2023 | 35.21B | -104.00M | -0.29% |
| Mar 31, 2022 | 35.31B | 18.71B | 112.66% |
| Mar 31, 2021 | 16.61B | 12.77B | 333.32% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,196.21B |
| Takeda Pharmaceutical Company | 4,480.25B |
| Daiichi Sankyo Company | 1,924.68B |
| HOYA Corporation | 876.09B |
| Otsuka Holdings | 2,401.70B |
| Terumo | 1,037.94B |
| Astellas Pharma | 1,944.99B |
| Shionogi & | 440.50B |